

## Labcorp expands therapeutic drug monitoring portfolio for precision medicine

21 February 2019 | News

**With the launch of the DoseASSURE CTZ, LabCorp now has the most comprehensive biologics TDM menu in the industry, targeting the largest number of biologic drugs.**



LabCorp®, a leading global life sciences company that is deeply integrated in guiding patient care, announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE™ portfolio. The new Certolizumab Concentration and Anti-Certolizumab Antibody DoseASSURE CTZ assay, helps physicians monitor individual drug response for patients who are on Certolizumab, a biologic drug used to treat certain inflammatory diseases, such as rheumatoid arthritis and Crohn's disease.

Biologic drugs are complex, protein-based therapies that can be used to treat certain inflammatory diseases and are among the fastest growing class of drugs available today. However, the expense of these medications and the variability in patient response can present numerous challenges. LabCorp's DoseASSURE portfolio helps address these challenges by providing quantitative, patient-specific measurement which can guide patient therapy. With the launch of the DoseASSURE CTZ, LabCorp now has the most comprehensive biologics TDM menu in the industry, targeting the largest number of biologic drugs.

"Biologic drugs can be life-changing, but individual patient response to biologics can vary greatly," said David P. King, LabCorp's chairman and CEO. "LabCorp's DoseASSURE portfolio helps to deliver on the promise of precision medicine by enabling more effective and more individualized treatment plans that can improve clinical outcomes at reduced costs."

Studies demonstrate the use of TDM can improve efficacy and prolong successful response to biologic treatment. Accordingly, appropriate use of TDM can diminish the need for disease-related surgery and hospitalization by reducing the risk of treatment failure.